A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects
A Randomized, Active Controlled, Double-blind, Multi-Centre Study to Evaluate Safety and Immunogenicity of One Dose of FLUVAL AB-like (Trivalent, Whole Virus, Aluminium Phosphate Gel Adjuvanted) Influenza Vaccine Containing 6μgHA of Seasonal A/H1N1, A/H3N2 and B Influenza Antigens in Non-elderly Adult and Elderly Subjects
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Budapest, Ungarn, 1083
- Family Doctor's Office
-
Budapest, Ungarn, 1136
- Family Doctor's Office
-
Pilisvörösvár, Ungarn, 2085
- Family Doctor's Office
-
-
Pest
-
Biatorbágy, Pest, Ungarn, 2051
- Péter Vajer
-
Hatvan, Pest, Ungarn, 3000
- Barna Bőze
-
Szentendre, Pest, Ungarn, 2000
- Family Doctor's Office
-
Vecsés, Pest, Ungarn, 2220
- Tibor Hrutka
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- male and female adult volunteers aged 18 years or older,
- mentally competent,
- able to understand and comply with all study requirements,
- willing and able to give written informed consent prior to initiation of study procedures,
- in good health (as determined by clinical judgement of the investigator on the basis of medical history and existing medical condition) or are in stable medical condition. Subjects will not be excluded with known, adequately treated, clinically significant organ or systemic diseases (e.g. asthma or diabetes), such that, in the opinion of the investigator, the significance of the disease will not compromise the subject's participation in the study.
- Female subjects aged 18 to 60 years (i.e. participants of childbearing potential) with a negative result from the urine pregnancy test prior to vaccination who agrees to use an acceptable contraception method or abstinence throughout the trial and not become pregnant for the duration of the study.
- Absence of existence of any exclusion criteria.
Exclusion Criteria:
- Pregnancy, breast-feeding or positive urine pregnancy test at baseline prior to vaccination. Female subjects who are able to bear children but not willing to use an acceptable contraception method for the duration of the study.
- Hypersensitivity to eggs, chicken protein, thiomersal, formaldehyde, gentamycin, ciprofloxacin, neomycin or any other component of the vaccine;
- History of anaphylactic shock or neurological symptoms or signs following administration of any vaccine;
- History of Guillain-Barré syndrome;
- Serious disease, such as cancer, autoimmune disease, advanced arteriosclerotic disease, complicated diabetes mellitus, acute or progressive hepatic disease, acute or progressive renal disease, congestive heart failure;
- Immunosuppressive therapy within the past 36 months;
- Concomitant corticosteroid therapy, including high-dose inhaled corticosteroids;
- Receipt of immunostimulants;
- Receipt of parenteral immunoglobulin, blood products and/or plasma derivates within the past 3 months;
- Suspected or known HIV, HBV or HCV infection;
- Acute disease and/or axillary temperature ≥37oC within the past 3 days;
- Vaccine therapy within the past 4 weeks;
- Influenza vaccination (any kind) within the past 6 months;
- Experimental drug therapy within the past 4 weeks;
- Concomitant participation in another clinical study;
- Any condition which, in the opinion of the investigator, may interfere with the evaluation of the study;
- Past or current psychiatric disease of the subject that upon judgement of the investigator may have effect on the objective decision-making of the subject;
- Alcohol or drug abuse of the subject.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: FAB-6011
One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μg HA of seasonal A/H1N1, A/H3N2 and B influenza antigens
|
Én 0,5 ml injeksjon av FAB-6011 trivalent influensavaksine som inneholder 6μgHA av sesongmessige A/H1N1, A/H3N2 og B influensa antigener.
Andre navn:
|
|
Aktiv komparator: FLUVALAB
One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μg HA of seasonal A/H1N1, A/H3N2 and B influenza antigens
|
Én 0,5 ml injeksjon av FLUVAL AB trivalent influensavaksine som inneholder 15μgHA av sesongmessige A/H1N1, A/H3N2 og B influensa antigener.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Measures of immunogenicity
Tidsramme: 21-28 days following vaccination
|
The measures of immunogenicity (by using HI test) are:
|
21-28 days following vaccination
|
|
Measures of safety
Tidsramme: 21-28 days following vaccination
|
The measures of safety are: Number and percentage of subjects with at least
|
21-28 days following vaccination
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Measures of long term immunogenicity
Tidsramme: 110-120 days following vaccination
|
The measures of long term immunogenicity (by using HI test) are:
|
110-120 days following vaccination
|
|
Measures of long term safety
Tidsramme: 110-120 days following vaccination
|
The measures of long term safety are: Number and percentage of subjects with at least
|
110-120 days following vaccination
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studieleder: Gabor Kollar, MD, Omninvest Ltd
- Hovedetterforsker: Ágnes Hasitz, MD, Family Doctor's Office, Szentendre
- Hovedetterforsker: Judit Simon, MD, Family Doctor's Office, Budapest
- Hovedetterforsker: Péter Torzsa, MD, Family Doctor's Office, Budapest
- Hovedetterforsker: Ferenc Tamás, MD, Family Doctor's Office, Pilisvörösvár
- Hovedetterforsker: Barna Bőze, MD, Family Doctor's Office, Hatvan
- Hovedetterforsker: Tibor Hrutka, MD, Family Doctor's Office, Vecsés
- Hovedetterforsker: Péter Vajer, MD, Family Doctor's Office, Biatorbágy
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- FluvalAB-H-15
- 2011-003314-16 (EudraCT-nummer)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .